A Retinal Bet With Big-Pharma Muscle and Blackstone Financing
Johnson & Johnson (NYSE: JNJ) is putting substantial capital behind a straightforward proposition: better control of retinal disease, potentially with more time between treatments, would be worth bringing into its pharmaceutical portfolio. On…
U.S. stocks finished Monday sharply lower, with the Nasdaq Composite falling 2.49%, the S&P 500 losing 1.92% and the Dow Jones Industrial Average declining 739.38 points. The markets realized losses across large-cap and small-cap shares, while the Cboe Volatility Index jumped 22.06%…
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
AlloSure Kidney Data Excites, Dupixent Sales Surge and POTENTIAL Competitor, EP-104GI, Nears December EoE Catalyst
Biotechnology’s most persuasive growth stories are moving beyond laboratory promise and into financial statements, clinical evidence and approaching trial milestones. CareDx (NASDAQ: CDNA) reported third-quarter revenue growth…
As SER-252 advances into its second dose cohort, Serina is building a case that improving how a medicine reaches patients can be as consequential as discovering the medicine itself.
Serina Therapeutics, Inc. (NYSE American: SER) is pursuing an appealing proposition in biotechnology:…
Nvidia-backed biotech pairs a clinical-stage cancer pipeline with pharmaceutical partnerships as TRex Bio, Retension and Lycia join the IPO queue
October 8, 2026
Artificial intelligence has spent the past several years promising to transform drug discovery. Iambic Therapeutics is now asking Wall…
Backed by AstraZeneca and Teradyne, the robotics company is betting that the next breakthrough in medicine will need a breakthrough on the factory floor.
Artificial intelligence can help design a promising medicine. It cannot deliver a dose by admiring its own calculations.…
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles.
The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a…
